NEW YORK, NY / ACCESSWIRE / March 17, 2017 / The Pawar Law Group announces a class action lawsuit on behalf of Galena Biopharma, Inc. (NASDAQ: GALE) investors who purchased Galena stock between August 11, 2014 and January 31, 2017, inclusive (the "Class Period"). The suit is for recovery of investor losses.

To participate in this class action lawsuit, visit the firm's website at http://pawarlawgroup.com/cases/galena-biopharma-inc/ or email Vik Pawar, Esq. at vik@pawarlawgroup.com or call toll free at (866) 999-0873.

No class has been certified in the above action yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

According to the complaint, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Galena's sales of Abstral were based on unsustainable sales and marketing practices; (2) such sales and marketing practices could subject Galena to a criminal investigation; and (3) as a result, Defendants' statements about Galena's business, operations, and prospects were false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

If you wish to serve as lead plaintiff, you must move the Court no later than April 14, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You may join the case here: http://pawarlawgroup.com/cases/galena-biopharma-inc/ or email Vik Pawar, Esq. at vik@pawarlawgroup.com.

Contact:

Vik Pawar, Esq.
Pawar Law Group
20 Vesey Street, Suite 1210
New York, NY 10007
Tel: (212) 571-0805
Fax: (212) 571-0938
vik@pawarlawgroup.com

SOURCE: Pawar Law Group